




Leader in scientifically proven essential fatty acid supplements for over 25 years

January 4, 2005



Office of Nutritional Products
Labelling and Dietary Supplements (HFS-810)
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Pkwy
College Park, MD 20740

RE: CLAIMS NOTIFICATION

a) Name and Address of the Manufacturer
Efamol Ltd.
Brackenholme Business Park
Brackenholme, Selby
North Yorkshire
YO8 6EL
United Kingdom

b) Text of the Statement that is being Made

In nursing infants, visual and cognitive development is associated with an adequate supply of two fatty acids in particular, docosahexaenoic acid (DHA) and arachidonic acid (AA). Most school age children find focusing and learning easy. A majority of those that don't are boys, who naturally have a higher requirement for essential fatty acids than girls. Normal body levels of DHA and AA are associated with normal behaviour and sleep patterns, and typical visual, auditory, language and reading performance. As well, normal reading, spelling and auditory working memory are correlated with healthy skin and nails, an indication of normal body fatty acid composition. Maintaining certain levels of DHA and AA is vital to promote and maintain eye and brain health and function. Supplementing the diet with Efalex® is a convenient way to ensure intake of these important nutrients that support and maintain healthy mental function and focus.*

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

c) The Name of the Dietary Supplement that is the Subject of the Statement
Efalex®

d) Certification

I, Peter Clough, certify the accuracy of the information presented and contained in this notice, that the information contained in the notice is complete and accurate, and that the notifying firm has substantiation that the statement is truthful and not misleading.

Signature: [Handwritten Signature] Date: 4th January 2005
Peter Clough, Managing Director, Efamol Ltd.

975 0162 LET 15365